This research study is studying a combination of two targeted therapies as a possible
treatment for Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation.
The drugs involved in this study are:
- Osimertinib (Tagrisso)
This research study is a Phase II clinical trial. Phase II clinical trials test the safety
and effectiveness of an investigational drug to learn whether the drugs work in treating a
specific disease. "Investigational" means that the drugs are being studied.
The EGFR gene produces a protein that helps cells divide. Specific changes or a mutation in
the genetic information causes abnormal cell division and can lead to lung cancer. Patients
who have NSCLC with an EGFR gene mutation can be treated by drugs called EGFR tyrosine kinase
inhibitors (EGFR TKIs). They may stop (or "inhibit") the effect of the mutation in the EGFR
Osimertinib alone has been shown to benefit some patients who have received prior treatment
for their EGFR-mutant NSCLC. The FDA (the U.S. Food and Drug Administration) has not approved
the combination of Osimertinib and Selumetinib as a treatment for any disease, but it has
been investigated in other clinical trials.
The main purpose of the study is to look at information on any potential side effects that
this drug combination may cause and collect data about how your cancer responds to the
combination of drugs.
Specific TKIs have been approved by the FDA for first-line treatment of NSCLC patients with
an EGFR mutation.
- Participants must have histologically confirmed stage IV NSCLC (per AJCC 7th edition)
from time of diagnosis with either the L858R or exon 19 deletion activating EGFR
mutation as identified in a CLIA-approved laboratory.
- Participants must have measurable disease, defined as at least one lesion that can be
accurately measured in at least one dimension (longest diameter to be recorded for
non-nodal lesions and short axis for nodal lesions) as ≥20 mm with conventional
techniques or as ≥10 mm with spiral CT scan, MRI, or calipers by clinical exam.
- Participants can have no prior history of any EGFR-directed therapy, including TKIs or
antibodies, and must also be chemotherapy and immunotherapy naïve for metastatic
disease. Patients who have completed adjuvant or neo-adjuvant chemotherapy > 6 months
ago are considered treatment naïve
- Participants must be aged ≥ 18 years
- Participants must have an ECOG performance status of 0-1 (Appendix A)
- Participants must have normal organ and marrow function as defined below:
- absolute neutrophil count ≥1,500/mcL
- platelets ≥100,000/mcL
- hemoglobin >9.0 g/dL
- total bilirubin < 1.5 times the ULN if no liver metastases or < 3 times the ULN
in the presence of documented Gilbert's syndrome (unconjugated
hyperbilirubinemia) or liver metastases
- AST(SGOT)/ALT(SGPT) <2.5 × institutional upper limit of normal or <5 times the
ULN in the presence of liver metastases
- creatinine ≤ 1.5 x institutional upper limit of normal OR
- creatinine clearance ≥50 mL/min as determined by the Cockcrft-Gault formula.
- Participants must have biopsy tissue at time of diagnosis available for targeted
next-generation sequencing. The testing does not have to be completed prior to study
enrollment. Biopsy can be performed at an outside institution as long as sufficient
tissue is available.
- Participants must be ≥2 weeks since any major surgery (excluding vascular access
placement, mediastinoscopy, or biopsies performed by an interventional service)
- Participants must be ≥2 weeks since any prior radiation, including CNS radiation
- Male patients: Willing to use adequate contraception (barrier or abstinence) while on
treatment with study drug and for 3 months after finishing treatment.
- Female patients: Willing to use adequate contraception (barrier or abstinence) at
least 2 weeks before receiving any study medication, while on treatment with study
drug, and for 3 months after finishing treatment.
- Female patients: Must not be pregnant or breast-feeding. Women of child-bearing
potential must have a negative pregnancy test prior to start of dosing or must have
evidence of non-child-bearing potential by fulfilling one of the following criteria at
- Post-menopausal defined as aged more than 50 years and amenorrheic for at least
12 months following cessation of all exogenous hormonal treatments
- Women under 50 years are considered postmenopausal if they have been amenorrheic
for 12 months or more following cessation of exogenous hormonal treatments and
with LH and FSH levels in the post-menopausal range for the institution.
- Documentation of irreversible surgical sterilization by hysterectomy, bilateral
oophorectomy, or bilateral salpingectomy but not tubal ligation
- Prior or ongoing treatment with any of the following:
- EGFR targeted therapy (TKI or antibody) or any other targeted therapies targeting the
- Any cytotoxic chemotherapy, investigational agents, or anticancer drugs for the
treatment of advanced NSCLC
- Prior radiotherapy within 2 weeks of the first dose of study treatment.
- No uncontrolled central nervous system (CNS) disease, including parenchymal brain
metastases, leptomeningeal disease, or spinal cord compression. Patients with
asymptomatic untreated brain metastases are eligible. Patients with treated CNS
disease will be allowed to enroll provided they have clinically confirmed stable
disease with ≥2 weeks since definitive CNS therapy (radiation or surgery) and ≥2 weeks
without systemic steroids. Patients may undergo either whole brain radiation or
stereotactic radiosurgery prior to study entry.
- History of allergic reactions attributed to compounds, or any of its excipients, of
similar chemical or biologic composition to osimertinib or selumetinib.
- Patients currently receiving and unable to stop using medications known to be potent
inhibitors or inducers of CYP3A4. The full list of medications that would make a
patient ineligible are provided in Appendix B, along with indicated washout times.
- Patients currently receiving and unable to stop high doses of supplemental vitamin E.
Selumetinib capsules contain vitamin E and high doses of vitamin E have been reported
to cause bleeding and interfere with blood coagulation processes.
- Any unresolved toxicities from prior therapy greater than Common Terminology Criteria
for Adverse Events (CTCAE) grade 1 at the time of starting study treatment.
- Malignancies within the past 3 years excluding adequately treated basal or squamous
cell carcinomas of the skin without local or distant metastases.
- Refractory nausea and vomiting, chronic gastrointestinal diseases, previous
significant bowel resection, or any process that compromises the ability to swallow or
absorb oral medication
- Significant medical history or unstable medical comorbidities, including:
- heart disease including congestive heart failure (NYHA Grade II or greater); unstable
angina; prior myocardial infarction (NSTEMI or STEMI) within 6 months prior to study
enrollment; hypertension with a systolic blood pressure of >150 mm Hg or diastolic
blood pressure of >100 mm Hg while on antihypertensive medication
- any clinically important abnormalities in rhythm, conduction or morphology of resting
ECG, e.g. complete left bundle branch block, third-degree heart block, second-degree
heart block, QT interval corrected by Fridericia's formula (QTcF) of >/= 450 ms in
males or >/= 470 ms in females
- any factors that increase the risk of QTc prolongation or risk of arrhythmic events
such as heart failure, hypokalemia, congenital long QT syndrome, family history of
long QT syndrome or unexplained sudden death under 40 years of age in first degree
relatives, or any concomitant medication known to the prolong the QT interval and
listed in Appendix B that a patient is unable to stop.
- past medical history of interstitial lung disease, drug-induced interstitial lung
disease, radiation pneumonitis which required steroid treatment, or any evidence of
clinically active interstitial lung disease
- active bleeding diatheses, which in the investigator's opinion makes it undesirable
for the patient to participate in the trial or which would jeopardize compliance with
- active infection or ongoing antiviral medication for viral infections including
hepatitis B, hepatitis C, or human immunodeficiency virus (HIV). Screening for chronic
conditions is not required. HIV-positive participants on combination antiretroviral
therapy are ineligible because of the potential for pharmacokinetic interactions with
selumetinib or osimertinib.
- left ventricular ejection fraction of < 45%
- Any evidence of severe or uncontrolled systemic diseases, including active bleeding
diatheses, which in the investigator's opinion makes it undesirable for the patient to
participate in the trial or which would jeopardize compliance with the protocol
- Known to be T790M+ (on pre-treatment tumor or plasma) or known germline T790M.
- Ophthalmological conditions as follows:
- Current or past history of retinal pigment epithelial detachment (RPED)/central serous
retinopathy (CSR) or retinal vein occlusion
- Uncontrolled glaucoma (irrespective of IOP)
- Males and females of reproductive potential who are not using an effective method of
birth control and females who are pregnant or breastfeeding or have a positive (urine
or serum) pregnancy test prior to study entry.
- Pregnant women are excluded from this study because the effects of selumetinib and
osimertinib on the development of the fetus are unknown, and there is potential for
teratogenic or abortifacient effects. Because there is an unknown but potential risk
for adverse events in nursing infants secondary to treatment of the mother with
selumetinib or osimertinib, breastfeeding should be discontinued if the mother is
treated with these agents.